The Analgesic Effect of Nitroglycerin Patch for Postoperative Pain After Total Knee Replacement
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00375362|
Recruitment Status : Unknown
Verified July 2006 by Rabin Medical Center.
Recruitment status was: Recruiting
First Posted : September 13, 2006
Last Update Posted : September 13, 2006
|Condition or disease||Intervention/treatment|
|Total Knee Arthroplasty||Drug: Nitroderm patch|
Patients undergoing total knee arthroplasty will be randomized into two groups: control and placebo.
Eache patient will undergo total knee arthroplasty under general anesthesia. Both groups will get the same anesthetic protocal. At the end of surgery, before awakening patients will recieve either a nitroglycerin or placebo patch on their back. Both the participant and the investigator will be blinded to the group assisignment. At the end of surgery both groups will recieve morphine for postoperative pain. In the recovery room they will be given patient controlled analgesia with morphine. An investigator blinded to study assisignment will record pain scores, sedation scores, nauseau and vomiting. Patients will be given patient controlled analgesia for 24 hours and they will be followed for pain levels, morphine use, sedation and nauseau levels. The nitroderm or placebo patch will be removed after 24 hours.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Analgesic Efficacy of Nitroglycerin Patches for Postoperative Pain in Patients Undergoing Total Knee Arthroplasty|
|Study Start Date :||July 2006|
|Estimated Study Completion Date :||September 2006|
- pain scores
- morphine use
- sedation score
- nausea and vomiting
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00375362
|Contact: Artium Lenchinsky, MD||937 6811|
|Rabin Medical Center||Recruiting|
|Petach Tikvah, Israel|
|Contact: Artium Lenchinsky 937-6811|
|Study Director:||Leonid A Eidelman, MD||Rabin Medical Center|
|Principal Investigator:||Sharon Orbach-Zinger, MD||Rabin Medical Center|